Predictive value of indirect bilirubin before neoadjuvant chemoradiotherapy in evaluating prognosis of local advanced rectal cancer patients

doi:10.4251/wjgo.v14.i11.2224

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2809)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-3) series.

Item

Count

PDF

144

WORD

HTML

1399

Figures (1-4)

196

Tables (1-3)

199

Sum=1983

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

234

Download

592

Sum=826

Nov 15, 2022 (publication date) through Nov 27, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Nov 15, 2022; 14(11): 2224-2237
Published online Nov 15, 2022. doi: 10.4251/wjgo.v14.i11.2224

Table 1 Clinical characteristics and treatment strategies of local advanced rectal cancer patients

Characteristic	Pre-IBIL ≤ 6.2 μmol/L (n = 163)	Pre-IBIL > 6.2 μmol/L (n = 161)	P value	All patients (n = 324)
Age, yr			0.305
< 60	88 (53.99)	97 (60.25)		185 (57.10)
≥ 60	75 (46.01)	64 (39.75)		139 (42.90)
Sex			0.007
Female	61 (37.42)	37 (22.98)		98 (30.25)
Male	102 (62.58)	124 (77.02)		226 (69.75)
BMI, kg/m²			0.317
< 18.5	7 (4.29)	4 (2.48)		11 (3.40)
18.5-23.9	86 (52.76)	73 (45.34)		159 (49.07)
24.0-27.9	52 (31.90)	66 (40.99)		118 (36.42)
≥ 28.0	18 (11.04)	18 (11.18)		36 (11.11)
Smoking history			0.581
No	87 (53.37)	80 (49.69)		167 (51.54)
Yes	76 (46.63)	81 (50.31)		157 (48.46)
Drinking history			0.925
No	96 (58.90)	93 (57.76)		189 (58.33)
Yes	67 (41.10)	68 (42.24)		135 (41.67)
Chronic disease history			0.624
No	100 (61.35)	104 (64.60)		204 (62.96)
Yes	63 (38.65)	57 (35.40)		120 (37.04)
cTNM stage			0.839
II	23 (14.11)	25 (15.53)		48 (14.81)
III	140 (85.89)	136 (84.47)		276 (85.19)
nCRT with surgery interval, d			0.573
31-60	88 (53.99)	79 (49.07)		167 (51.54)
61-90	63 (38.65)	66 (40.99)		129 (39.81)
> 90	12 (7.36)	16 (9.94)		28 (8.64)
Inferior margin			0.373
≤ 5 cm	109 (66.87)	116 (72.05)		225 (69.44)
> 5 cm	54 (33.13)	45 (27.95)		99 (30.56)
TRG			0.160
1	14 (8.59)	16 (9.94)		30 (9.26)
2	90 (55.21)	72 (44.72)		162 (50.00)
3	41 (25.15)	43 (26.71)		84 (25.93)
4	18 (11.04)	30 (18.63)		48 (14.81)
Vascular invasion			0.471
Negative	155 (95.09)	149 (92.55)		304 (93.83)
Positive	8 (4.91)	12 (7.45)		20 (6.17)
Neural invasion			0.846
Negative	130 (79.75)	126 (78.26)		256 (79.01)
Positive	33 (20.25)	35 (21.74)		68 (20.99)
Radiotherapy type before surgery			0.688
VMAT	146 (89.57)	140 (86.96)		286 (88.27)
IMRT	14 (8.59)	16 (9.94)		30 (9.26)
3D-CRT	3 (1.84)	5 (3.11)		8 (2.47)
Chemotherapy type before surgery			0.975
Capecitabine	145 (88.96)	144 (89.44)		289 (89.20)
Capecitabine + platinum	9 (5.52)	9 (5.59)		18 (5.56)
Other	9 (5.52)	8 (4.97)		17 (5.25)
Adjuvant chemotherapy			0.383
No	57 (34.97)	48 (29.81)		105 (32.41)
Yes	106 (65.03)	113 (70.19)		219 (67.59)
Pre-CEA			0.832
≤ 5 ng/mL	91 (55.83)	87 (54.04)		178 (54.94)
> 5 ng/mL	72 (44.17)	74 (45.96)		146 (45.06)
Pre-CA19-9			0.931
≤ 27 U/mL	131 (80.37)	131 (81.37)		262 (80.86)
> 27 U/mL	32 (19.63)	30 (18.63)		62 (19.14)

nCRT: Neoadjuvant chemoradiotherapy; pre-IBIL: Indirect bilirubin before neoadjuvant chemoradiotherapy; BMI: Body mass index; TRG: Tumor regression grade; VMAT: Volumetric modulated arc therapy; IMRT: Intensity modulated radiation therapy; 3D-CRT: 3-dimensional conformal radiation therapy; pre-CEA: Carcinoembryonic antigen before neoadjuvant chemoradiotherapy; pre-CA19-9: Carbohydrate antigen 19-9 before neoadjuvant chemoradiotherapy.

Table 2 Cox regression analysis of prognostic factors for overall survival

Characteristic	Univariable analysis		Multivariable analysis
Characteristic	HR (95%CI)	P value	HR (95%CI)	P value
Pre-IBIL
≤ 6.2 μmol/L	Reference		Reference
> 6.2 μmol/L	1.71 (1.01-2.87)	0.045	1.77 (1.04-3.01)	0.035
Age, yr
< 60	Reference
≥ 60	1.39 (0.84-2.31)	0.199
Sex
Female	Reference
Male	1.16 (0.66-2.04)	0.596
BMI, kg/m²
< 18.5	Reference
18.5-23.9	0.74 (0.23-2.43)	0.624
24.0-27.9	0.57 (0.17-1.93)	0.370
≥ 28.0	0.27 (0.05-1.32)	0.105
Smoking history
No	Reference		Reference
Yes	0.57 (0.34-0.97)	0.039	0.58 (0.34-1.00)	0.048
Drinking history
No	Reference
Yes	0.72 (0.42-1.23)	0.227
Chronic disease history
No	Reference
Yes	1.09 (0.65-1.82)	0.749
cTNM stage
II	Reference
III	2.54 (0.92-6.99)	0.072
nCRT with surgery interval, day
31-60	Reference
61-90	0.61 (0.35-1.07)	0.083
> 90	0.68 (0.24-1.92)	0.469
Inferior margin
≤ 5 cm	Reference
> 5 cm	0.91 (0.53-1.59)	0.752
TRG
1	Reference		Reference
2	0.35 (0.18-0.67)	0.002	0.37 (0.18-0.75)	0.006
3	0.23 (0.10-0.52)	< 0.001	0.27 (0.12-0.64)	0.003
4	0.17 (0.06-0.48)	< 0.001	0.18 (0.06-0.53)	0.002
Vascular invasion
Negative	Reference		Reference
Positive	3.79 (1.86-7.74)	< 0.001	2.93 (1.39-6.21)	0.005
Neural invasion
Negative	Reference		Reference
Positive	2.15 (1.26-3.69)	0.005	1.27 (0.69-2.31)	0.442
Radiotherapy type before surgery
VMAT	Reference
IMRT	1.68 (0.85-3.35)	0.137
3D-CRT	0.69 (0.09-4.98)	0.709
Chemotherapy type before surgery
Capecitabine	Reference
Capecitabine + platinum	1.45 (0.57-3.66)	0.431
Other	1.90 (0.76-4.78)	0.172
Adjuvant chemotherapy
No	Reference
Yes	0.60 (0.36-1.00)	0.050
Pre-CEA
≤ 5 ng/mL	Reference
> 5 ng/mL	1.44 (0.87-2.39)	0.158
Pre-CA19-9
≤ 27 U/mL	Reference		Reference
> 27 U/mL	2.05 (1.19-3.54)	0.010	2.05 (1.16-3.62)	0.014

HR: Hazard ratio; 95%CI: 95% confidence interval; nCRT: Neoadjuvant chemoradiotherapy; pre-IBIL: Indirect bilirubin before neoadjuvant chemoradiotherapy; BMI: Body mass index; TRG: Tumor regression grade; VMAT: Volumetric modulated arc therapy; IMRT: Intensity modulated radiation therapy; 3D-CRT: 3-dimensional conformal radiation therapy; pre-CEA: Carcinoembryonic antigen before neoadjuvant chemoradiotherapy; pre-CA19-9: Carbohydrate antigen 19-9 before neoadjuvant chemoradiotherapy.

Table 3 Cox regression analysis of prognostic factors for disease-free survival

Characteristic	Univariable analysis		Multivariable analysis
Characteristic	HR (95%CI)	P value	HR (95%CI)	P value
Pre-IBIL
≤ 6.2 μmol/L	Reference		Reference
> 6.2 μmol/L	1.68 (1.12-2.53)	0.013	1.86 (1.22-2.84)	0.004
Age, yr
< 60	Reference
≥ 60	1.16 (0.78-1.74)	0.456
Sex
Female	Reference
Male	0.84 (0.55-1.28)	0.414
BMI, kg/m²
< 18.5	Reference		Reference
18.5-23.9	0.64 (0.26-1.61)	0.346	0.46 (0.18-1.17)	0.102
24.0-27.9	0.62 (0.24-1.57)	0.312	0.50 (0.19-1.30)	0.157
≥ 28.0	0.25 (0.07-0.87)	0.029	0.19 (0.05-0.66)	0.009
Smoking history
No	Reference
Yes	0.72 (0.48-1.08)	0.108
Drinking history
No	Reference
Yes	0.71 (0.47-1.07)	0.103
Chronic disease history
No	Reference
Yes	1.07 (0.72-1.61)	0.732
cTNM stage
II	Reference
III	1.49 (0.80-2.80)	0.210
nCRT with surgery interval, d
31-60	Reference		Reference
61-90	0.64 (0.41-0.99)	0.047	0.63 (0.40-0.99)	0.044
> 90	0.84 (0.40-1.77)	0.655	0.63 (0.29-1.35)	0.235
Inferior margin
≤ 5 cm	Reference
> 5 cm	0.80 (0.51-1.25)	0.318
TRG
1	Reference		Reference
2	0.45 (0.26-0.79)	0.006	0.43 (0.24-0.78)	0.005
3	0.29 (0.15-0.57)	< 0.001	0.30 (0.15-0.62)	0.001
4	0.31 (0.15-0.66)	0.002	0.31 (0.14-0.70)	0.005
Vascular invasion
Negative	Reference		Reference
Positive	2.54 (1.32-4.90)	0.005	2.24 (1.13-4.44)	0.021
Neural invasion
Negative	Reference		Reference
Positive	1.82 (1.17-2.82)	0.008	1.34 (0.82-2.18)	0.238
Radiotherapy type before surgery
VMAT	Reference
IMRT	1.07 (0.57-2.01)	0.836
3D-CRT	0.83 (0.20-3.37)	0.791
Chemotherapy type before surgery
Capecitabine	Reference
Capecitabine + platinum	0.98 (0.43-2.26)	0.969
Other	1.56 (0.72-3.37)	0.262
Adjuvant chemotherapy
No	Reference
Yes	0.89 (0.59-1.35)	0.584
Pre-CEA
≤ 5 ng/mL	Reference
> 5 ng/mL	1.33 (0.89-1.98)	0.158
Pre-CA19-9
≤ 27 U/mL	Reference
> 27 U/mL	1.47 (0.92-2.33)	0.104

Citation: Li SF, Wei R, Yu GH, Jiang Z. Predictive value of indirect bilirubin before neoadjuvant chemoradiotherapy in evaluating prognosis of local advanced rectal cancer patients. World J Gastrointest Oncol 2022; 14(11): 2224-2237
URL: https://www.wjgnet.com/1948-5204/full/v14/i11/2224.htm
DOI: https://dx.doi.org/10.4251/wjgo.v14.i11.2224